Skip to main content
Equibles
OFIX logo

OFIX · Orthofix Medical Inc.

Track OFIX — free

Use OFIX with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about OFIX

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.01 +0.00 (+0.00%)
Market Cap
$407.73M
Shares
40.73M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$10.01 Open$10.33 Day$9.98–10.52 52W close$8.95–16.23 Avg vol 30d343K Short int2.1M · 5.2% float · 7.4d Short vol68% Last earningsAug 5, 2026 DataJan 2020–Aug 2026 Filing10-Q · Aug 5

Up next

Next earnings call
Nov 5, 2026 Est · unconfirmed · in 11 wks
FQ3-26 quarter ends
~Sep 23, 2026 Est
Latest filing: 10-Q
filed Aug 5, 2026

AI Brief

TL;DR.

Bullish
    Bearish

      AI-generated from the earnings call and 8-K · may contain errors · not investment advice

      Ask ALVIS about this →

      Equibles Rating

      blended score · not investment advice
      Overall
      Sell
      SellHoldBuy
      Technical Strong Sell Momentum Very Weak Sentiment Neutral Fundamentals Strong Quant / Vol Very High
      Market backdrop VIX 16 · calm Equity put/call 0.58
      Technical
      price trend
      Strong Sell
      50 / 200-day cross No cross
      Price vs 200-day avg −21%
      below
      Price vs 50-day avg −6%
      below
      RSI (14) 41
      neutral
      MACD trend Negative
      52-week position 15%
      near low
      Momentum
      relative strength
      Very Weak
      1-month return −9%
      trailing
      6-month return −26%
      trailing
      YTD return −34%
      this year
      Relative strength −37%
      vs S&P · 6-mo
      Sentiment
      smart money
      Neutral
      Trend (MA cross) No cross
      50d $11 › 200d $13 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +27 funds added
      Insider flow Distributing
      Net -$450.2K over 90 days · 100% sells
      Short interest Falling
      5.21% of float · ▼ -15.4% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      142 holders — mid 3-yr range
      Squeeze score 64
      elevated · 0–100
      Fundamentals
      Strong
      Revenue growth +3%
      Y/Y
      Gross margin 69%
      expanding
      EPS growth +29%
      Y/Y
      Free cash flow $-26.9M
      Buyback $75.0M
      authorized
      Balance sheet $75.4M
      net debt
      Quant / Vol
      risk profile
      Very High
      Volatility 47%
      annualized · 1-yr
      Max drawdown −45%
      past year
      ATR 5.5%
      of price · 14-day

      Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

      Guidance & track record

      Beat or met 3 of last 3
      Latest guidance · from the 8-K filed Aug 5, 2026
      full-year 2026
      Net sales Non-GAAP Initiated $845M – $855M
      Non-GAAP adjusted EBITDA Non-GAAP Initiated $95M – $98M
      2026
      Adj. EBITDA Non-GAAP $95M – $98M
      Prior guidance period ended · from the 8-K filed Nov 4, 2025
      Pro forma non-GAAP adjusted EBITDA · full-year 2025 $84M – $86M
      Pro Forma Adj. EBITDA · Full-Year 2025 $84M – $86M
      Guided vs delivered · last 3 settled
      Pro Forma Net Sales Full-Year 2025
      guided $808M – $816M
      $822.31M Beat +1.3%
      Net sales full-year 2024
      guided $785M – $795M
      $799.49M Beat +1.2%
      Revenue full year 2023
      guided $739M – $744M
      $746.64M Beat +0.7%

      Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

      Technicals

      trend & momentum for long-term holders Strong Sell
      4 · 2 · 0
      50 / 200-day cross
      No cross Neutral
      Price vs 200-day avg
      −21% Bearish
      Price vs 50-day avg
      −6% Bearish
      RSI (14)
      41 Neutral
      MACD trend
      Negative Bearish
      52-week position
      15% Bearish
      Market signals — smart money & positioning
      Bearish · 2 of 6
      Trend (MA cross) No cross
      50d $11 › 200d $13 — 200d above 50d
      Institutional flow Distributing
      -3% holders QoQ · +27 funds added
      Insider flow Distributing
      Net -$450.2K over 90 days · 100% sells
      Short interest Falling
      5.21% of float · ▼ -15.4% MoM · 7.4 days cover
      Volume signal Normal
      Volume near normal
      Institution breadth Steady
      142 holders — mid 3-yr range
      Price context
      position in its 52-week range
      Range low $9 Now $10 · 15% Range high $16
      vs 200-day avg -21% vs 50-day avg -6%

      Illustrative technical + ownership context — a signal mix, not investment advice.

      Key metrics

      the company's own KPIs, from written earnings releases and filings
      Metric Latest Period YoY
      Adjusted EBITDA non-GAAP $29.83M Six Months Ended June 30 —
      Adjusted EBITDA as a percentage of pro forma net sales non-GAAP 7.3% Six Months Ended June 30, 2026 —
      Adjusted EBITDA as a percentage of reported net sales non-GAAP 7.3% Six Months Ended June 30, 2026 —
      Adjusted gross margin as a percentage of pro forma net sales non-GAAP 71.2% Six Months Ended June 30, 2026 —
      Adjusted gross margin as a percentage of reported net sales non-GAAP 71.2% Six Months Ended June 30, 2026 —
      Adjusted gross profit non-GAAP $290.11M Six Months Ended June 30 —
      Adjusted net income (loss) non-GAAP -$1.69M Six Months Ended June 30 —
      Free cash flow non-GAAP -$47.14M Six Months Ended June 30 —
      Non-GAAP adjusted EBITDA non-GAAP $20.1M Q2 2026 —
      Non-operating expense, as adjusted non-GAAP $6.11M Three Months Ended June 30 —
      Research and development expense, as adjusted non-GAAP $15.45M Three Months Ended June 30 —
      Sales, general, and administrative expense, as adjusted non-GAAP $133.2M Three Months Ended June 30 —
      free cash flow (excluding M6-related restructuring charges) non-GAAP $3.1M Full-year 2025 —
      non-GAAP pro forma adjusted EBITDA non-GAAP $29.2M Q4 2025 —

      Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

      Versus peers

      Medical Devices — same industry group
      Open screener →
      Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
      OFIX
      Orthofix Medical Inc.
      this stock
      		$407.73M -34.0% +2.9% — 5.2%
      ABT
      Abbott Laboratories
      		 $198.81B -8.9% +5.7% 32.0 1.3%
      SYK
      Stryker Corp
      		 $127.26B -6.8% +11.2% 34.4 2.2%
      MDT
      Medtronic plc
      		 $119.47B -3.9% +8.4% 25.0 1.4%
      BSX
      Boston Scientific Corp
      		 $71.55B -48.2% +12.5% 20.0 1.5%

      Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

      At a glance

      key data from every section
      Ownership
      Institutional Holders Accumulating
      Holders
      142
      % held
      94.0%
      Net QoQ
      +2.1M sh
      Top holder
      Engine Capital Management…
      Held Float
      View
      Held by Funds
      Fund positions
      183
      View
      Short & Settlement
      Short Interest Falling
      Shares short
      2.1M
      Days to cover
      7.4d
      Change
      -387.0K sh
      View
      Short Volume
      Short vol %
      68%
      As of
      Aug 21, 2026
      Short Total
      View
      Fails to Deliver
      FTD shares
      98
      Value
      $1.2K
      As of
      Jul 31, 2026
      View
      Off-Exchange
      Off-exchange %
      31.3%
      Week of
      Jul 13, 2026
      Off-exch Lit
      View
      Smart Money
      Insider Trades Net selling
      Net (90d)
      -$450.2K
      Buyers / Sellers
      0 / 3
      Buyers Sellers
      View
      Financials
      Financials
      Revenue (FY)
      $822.3M
      Net income (FY)
      $-92.2M
      EPS diluted
      $-2.33
      View
      Buybacks
      Authorized
      $75.0M
      View
      Filings
      SEC Filings
      Latest
      Investor Event Transcript
      Filed
      Aug 12, 2026
      This year
      15
      View
      Proposed Sales
      Value
      $926.0K
      Shares
      66.7K
      Filed
      Dec 21, 2023
      View
      Earnings & Events
      Earnings Calls
      Last call
      Aug 12, 2026
      View
      Investor Relations
      Latest news
      Orthofix Reports Second Quarter 2…
      Published
      Aug 5, 2026
      View

      Performance

      5D 20D 120D MTD YTD
      OFIX -1.7% -8.7% -26.0% -15.2% -34.0%
      SPY -2.0% +3.3% +11.2% +2.1% +11.8%
      vs SPY +0.3% -12.0% -37.2% -17.3% -45.8%

      Capital returns

      Buyback program · as of Dec 31, 2017
      Authorized
      $75.00M
      Spent (derived)
      —
      Remaining
      —

      Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

      Key facts CIK 884624 CUSIP 68752M108 13F (30d) 131 filings 129 filers Visit website Investor relations

      Report a Problem

      Category
      Description
      Email (optional, for follow-up)